Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer model

Vijayalingam, S.; Kuppuswamy, Mohan; Subramanian, T.; Strebeck, F F; West, Cheri L.; Varvares, Mark A.; Chinnadurai, G.

doi:10.1038/cgt.2014.22

Cited by 7 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an immunocompetent Syrian hamster animal model of HNC, Vijayalingam et al 14 evaluated the effect of two apoptogenic human adenovirus (HAdV) vectors. They established two cell lines of hamster cheek pouch squamous cell carcinomas, induced by treatment with 9,10-dimethyl-1,2-benzanthracene.…”

Section: Oncolytic Virotherapymentioning

confidence: 99%

Oncolytic virotherapy for head and neck cancer: current research and future developments

Malhotra

Sendilnathan

Old

et al. 2015

View full text Add to dashboard Cite

Head and neck cancer (HNC) is the sixth most common malignancy worldwide. Despite recent advancements in surgical, chemotherapy, and radiation treatments, HNC remains a highly morbid and fatal disease. Unlike many other cancers, local control rather than systemic control is important for HNC survival. Therefore, novel local therapy in addition to systemic therapy is urgently needed. Oncolytic virotherapy holds promise in this regard as viruses can be injected intratumorally as well as intravenously with excellent safety profiles. This review will discuss the recent advancements in oncolytic virotherapy, highlighting some of the most promising candidates and modifications to date.

show abstract

Section: Oncolytic Virotherapymentioning

confidence: 99%

Oncolytic virotherapy for head and neck cancer: current research and future developments

Malhotra

Sendilnathan

Old

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Despite surgical advances and aggressive multimodality therapy, the prognosis for advanced HNSCCs is poor (<25% survival rate after five years) [ 2 , 3 ]. One promising approach to improve the treatment of HNSCCs is oncolytic virotherapy, which aims to destroy tumors by direct virus-mediated cell lysis and by the induction of antitumor immunity [ 4 ], as it is actively pursued with oncolytic adenoviral vectors (oAVs) [ 5 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas

Nilson¹,

Krutzke²,

Wienen³

et al. 2023

Viruses

View full text Add to dashboard Cite

Human multipotent mesenchymal stromal cells (hMSCs) are of significant therapeutic interest due to their ability to deliver oncolytic adenoviruses to tumors. This approach is also investigated for targeting head and neck squamous cell carcinomas (HNSCCs). HAdV-5-HexPos3, a recently reported capsid-modified vector based on human adenovirus type 5 (HAdV-5), showed strongly improved infection of both hMSCs and the HNSCC cell line UM-SCC-11B. Given that, we generated life cycle-unmodified and -modified replication-competent HAdV-5-HexPos3 vector variants and analyzed their replication within bone marrow- and adipose tissue-derived hMSCs. Efficient replication was detected for both life cycle-unmodified and -modified vectors. Moreover, we analyzed the migration of vector-carrying hMSCs toward different HNSCCs. Although migration of hMSCs to HNSCC cell lines was confirmed in vitro, no homing of hMSCs to HNSCC xenografts was observed in vivo in mice and in ovo in a chorioallantoic membrane model. Taken together, our data suggest that HAdV-5-HexPos3 is a potent candidate for hMSC-based oncolytic therapy of HNSCCs. However, it also emphasizes the importance of generating optimized in vivo models for the evaluation of hMSC as carrier cells.

show abstract

“…These advantages are why many consider hamsters a superior alternative to other small animals for use in research. For the development of vaccines and therapeutic approaches, some consider hamsters a higher standard as small animal model than mice and as such hamsters have been utilized in a wide range of models, from those examining diabetes, atherosclerosis, neural plasticity, to cancer (Table 1) (Bhathena et al 2011;Dillard et al 2010;Jové et al 2013;Staffend and Meisel 2012;Woods et al 2015;Vijayalingam et al 2014). However, the use of hamsters for models of pathogenic human diseases may be the most valuable due to comparable disease progression seen in hamsters to that of humans for many infectious diseases including bacteria, viruses, and parasites (Dondji et al 2008; da Silva-Couto et al 2015;Kuehne et al 2014;Safronetz et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Syrian Hamsters as a Small Animal Model for Emerging Infectious Diseases: Advances in Immunologic Methods

Warner

Safronetz

Kobinger

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

The use of small animal models for the study of infectious disease is critical for understanding disease progression and for developing prophylactic and therapeutic treatment options. For many diseases, Syrian golden hamsters have emerged as an ideal animal model due to their low cost, small size, ease of handling, and ability to accurately reflect disease progression in humans. Despite the increasing use and popularity of hamsters, there remains a lack of available reagents for studying hamster immune responses. Without suitable reagents for assessing immune responses, researchers are left to examine clinical signs and disease pathology. This becomes an issue for the development of vaccine and treatment options where characterizing the type of immune response generated is critical for understanding protection from disease. Despite the relative lack of reagents for use in hamsters, significant advances have been made recently with several hamster specific immunologic methods being developed. Here we discuss the progress of this development, with focus on classical methods used as well as more recent molecular methods. We outline what methods are currently available for use in hamsters and what is readily used as well as what limitations still exist and future perspectives of reagent and assay development for hamsters. This will provide valuable information to researchers who are deciding whether to use hamsters as an animal model.

show abstract

Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer model

Cited by 7 publications

References 37 publications

Oncolytic virotherapy for head and neck cancer: current research and future developments

Oncolytic virotherapy for head and neck cancer: current research and future developments

Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas

Syrian Hamsters as a Small Animal Model for Emerging Infectious Diseases: Advances in Immunologic Methods

Contact Info

Product

Resources

About